MedTrace Logo

Modeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity

NCT06699810 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-04-08

No results posted yet for this study

Summary

The goal of this study is to quantify day-to-day changes in blood glucose during treatment towards remission in ketosis-prone diabetes (KPDM) and describe them using a mathematical model of KPDM pathogenesis and remission.

Conditions

  • Ketosis Prone Diabetes

Interventions

DEVICE

Continuous Glucose Monitoring

After insulin discontinuation participants continue wearing their CGMs, for a total of 3 months.

DRUG

Insulin

Participants will receive standard-of-care insulin treatment. Insulin dosing will be adjusted based on CGM glucose readings.

Sponsors & Collaborators

  • Emory University

    lead OTHER

Principal Investigators

  • Priyathama Vellanki, MD, MS · Emory University

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-23
Primary Completion
2026-06-30
Completion
2026-06-30
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06699810 on ClinicalTrials.gov